Volume | 211,280 |
|
|||||
News | - | ||||||
Day High | 9.243 | Low High |
|||||
Day Low | 8.79 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Solid Biosciences Inc | SLDB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
9.17 | 8.79 | 9.243 | 8.95 | 9.30 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,783 | 211,280 | $ 9.05 | $ 1,911,084 | - | 1.81 - 15.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:56:27 | 25 | $ 9.04 | USD |
Solid Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
337.92M | 37.76M | - | 0 | -96.02M | -2.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Solid Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLDB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.44 | 10.99 | 8.79 | 9.80 | 139,886 | -1.49 | -14.27% |
1 Month | 9.13 | 10.99 | 7.95 | 9.54 | 196,531 | -0.18 | -1.97% |
3 Months | 9.62 | 15.05 | 7.95 | 11.45 | 246,650 | -0.67 | -6.96% |
6 Months | 2.66 | 15.05 | 2.21 | 7.94 | 366,855 | 6.29 | 236.47% |
1 Year | 6.35 | 15.05 | 1.81 | 6.55 | 249,576 | 2.60 | 40.94% |
3 Years | 53.085 | 74.25 | 1.81 | 24.41 | 538,555 | -44.14 | -83.14% |
5 Years | 91.50 | 203.70 | 1.81 | 54.45 | 840,119 | -82.55 | -90.22% |
Solid Biosciences Description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of speciality and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |